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DISCUSSION
DrCynthia K. Shortell (Durham, NC). The appropriate use of
IVC filters during venous lysis has not been previously addressed in a
systematic fashion. The questions, as I see it, are: Should everyone get
a filter? Should no one get a filter? Or should some people get a filter?
And if so, what determines that -- clot burden, hypercoagulable state,
prior history of pulmonary embolism, use of mechanical thrombec-
tomy devices, or something else?
To this end, I have the following questions for the authors. In
the Methods section of the manuscript, the authors state that the
decision to place an IVC filter was “provider specific.” In the
Procedures section, it stated that IVC filters were placed in 16% of
patients, or 11 patients, and that in addition, three patients had
existing IVC filters. So that, in total, 21% of patients included in the
analysis were actually protected by IVC filters.
Since the manuscript that I received, you have addressed this
issue partially in the slides that you presented today. But consider
this, additionally as the indications for filter placement are vague, is
it possible that the patients at highest risk for pulmonary embolism,
either because of past history of PE or because of intercurrent risk
factors, had filters in place for the procedure?
The authors do not comment on the role of optional filters or
retrievable filters in this setting. Has their attitude toward filter place-
ment changed since the introduction of these devices? How many of
the filters placed were retrievable and how many were retrieved?
What were the clinical features of the patients who had late
PE? Were they life-threatening events? Given that three patients
had late PEs, a high percentage in a small study, and that PE results
from recurrent DVT, would the authors consider recommending a
selective policy of permanent filters in these patients?
The authors note that only three complications occurred,
none of them related to IVC filter, in the 14 patients who had
them, including the 11 fresh filters. The authors also alternatively
could conclude that IVC filter use is safe in the setting of throm-
bolysis for DVT. Do the results presented really support the
conclusion of the abstract, namely, that CDT for DVT is safe and
effective, and that IVC filter is not required, presumably, ever?
Given the relatively low complication rate of IVC filters,
including in your own study, and the potentially fatal consequence
of PE even if rare, how do the authors justify their absolute
commitment to this conservative approach?
Dr Clinton D. Protack. Thank you Dr Shortell for reviewing
the manuscript and for your kind comments and questions. Ad-
dressing your three main questions we believe: (1) not everyone
should receive an IVC filter, (2) IVC filters provide a treatment
role in certain patients, (3) patients with prior PE, patients with
free-floating thrombus at the end of CDT, and those patients with
IVC thrombus would benefit from IVC filter placement.
I would agree that those with pre-existing filters had been
deemed high risk before we saw them. As we did a retrospective
study, we can only go with provider specific placement.We have no
unit guidelines and we do not systematically place IVC filters
before therapy. Given this environment, we would conclude that
based on the clinical judgment of the provider at the time of
procedure the patients were at high risk of a PE.
With regards to retrievable IVC filters, two of the 11 filters
placed were retrievable. The study spans a decade in which there
were no retrievable filters to the present where there are several.
Looking at the last 3 years we have only placed retrievable IVC
filters in clots that extended into the IVC. We have not seen a
major shift to placement just because we can retrieve them.
The study, while one of the largest in the current literature, is
perhaps too small to address a policy of permanent IVC filters in
high risk patients. At present, these three failures occurred on
anticoagulation. They, thus, met the criteria of failure of anticoag-
ulation, and we would place permanent filters. We would go with
the guidelines in these situations.
I think that is not an unreasonable argument that IVC filter
use is safe in the setting of thrombolysis for DVT. Following, I
would say that using a selective rather than a universal policy is
safer. However, following the same thinking, we also found no
benefit for filter placement. So while they do no harm, they provide
no benefit, and add a financial cost.
If we look at the success of CDT, it is excellent with a low
morbidity. In our hands, we did not suffer significant problems
because we did not routinely place a filter. We would agree that in
the right setting and the appropriate patient, IVC filter placement
remains a safe procedure. The enemy of good can often be better.
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